Scoping review demonstrates the role of emerging molecular biomarkers in head-and-neck squamous cell carcinoma, highlighting their importance for early detection and disease monitoring.
Head-and-neck cancers (HNCs) refer to a diverse group of cancers that originate in the soft tissues of the head-and-neck area. This category includes all tumors that start in areas such as the oral cavity, pharynx, larynx, thyroid gland, and cervical esophagus. The application of biomarkers in managing HNCs has grown significantly due to advances in genomics, proteomics, transcriptomics, and related technologies. These biomarkers are valuable for the early diagnosis of head-and-neck squamous cell carcinoma (HNSCC) and play a crucial role in enhancing patient outcomes. HNSCC develops through a series of stages marked by the accumulation of phenotypic and genetic alterations. Identifying particular biomarkers is crucial for specifying the various stages of cancer, making it essential for managing HNSCC. The absence of appropriate biomarkers for monitoring disease progression can result in a poor prognosis due to late-stage diagnosis. The objective of this review is to highlight emerging biomarkers relevant to HNSCC, covering primary locations such as the oral cavity, oropharynx, hypopharynx, larynx, and thyroid.
No takes yet. Share an insight, caveat, or question.
Santosh Kumar Swain (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: